Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial.
Marconi VC, Ramanan AV, de Bono S, Kartman CE, Krishnan V, Liao R, Piruzeli MLB, Goldman JD, Alatorre-Alexander J, de Cassia Pellegrini R, Estrada V, Som M, Cardoso A, Chakladar S, Crowe B, Reis P, Zhang X, Adams DH, Ely EW; COV-BARRIER Study Group.
.
.
Interrelationships between population and development.
Tabah L.Tabah L.
. Cancer Sci. 2021 Sep 10. doi: 10.1111/cas.15131. Online ahead of print.Cancer Sci. 2021.PMID: 34506683Free article.
.